within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX12_Tafasitamab;
model Tafasitamab 
   extends Pharmacolibrary.Drugs.ATC.L.L01FX12;

  annotation(Documentation(
    info ="<html><body><p>Tafasitamab is a humanized monoclonal antibody targeting CD19, used in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is FDA approved for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for patients with relapsed or refractory DLBCL receiving tafasitamab intravenously. PK parameters are for adult patients as described in registration trials and FDA/EMA assessment reports.</p><h4>References</h4><ol><li><p>Hoy, SM (2020). Tafasitamab: First Approval. <i>Drugs</i> 80(16) 1731â€“1737. DOI:<a href=&quot;https://doi.org/10.1007/s40265-020-01405-w&quot;>10.1007/s40265-020-01405-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32946059/&quot;>https://pubmed.ncbi.nlm.nih.gov/32946059</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Tafasitamab;
